|
**Overview**: Sphingolipidosis 3 Panel**Introduction**: The Sphingolipidosis 3 Panel is a diagnostic tool designed to screen for sphingolipidosis disorders using whole blood samples. In India, Gaucher (GBA), Niemann-Pick A/B (SMPD1), and Fabry (GLA) are among the most treatable lysosomal storage disorders, with enzyme replacement therapy available for Gaucher and Fabry, but often diagnosed late due to nonspecific symptoms (hepatosplenomegaly, pain, angiokeratomas). High morbidity from under-testing in rural/low-SES children/adults with unexplained organomegaly or acroparesthesia, limited genetic labs, delayed therapy leading to irreversible bone/lung/renal damage. Per pediatrics/genetics practices aligned with ICMR and Indian Society for Inborn Errors of Metabolism guidelines, the test employs PCR for 3 key genes over 1-2 days with high accuracy, valuable for focused screening in suspected cases. This diagnostic falls under genetic disorder screening and targets patients with hepatosplenomegaly, neuropathic pain, or family history, addressing accurate detection to guide enzyme replacement or substrate reduction. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early identification of treatable disorders and reducing long-term complications. Its whole blood-based approach ensures reliable mutation detection.**Other Names**: Sphingo 3 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: Focused LSD panels standard; in India, expanding in IEM centers.**Purpose**: The test assesses 3 parameters including GBA (Gaucher) to guide sphingolipidosis screening, detect mutations, inform enzyme therapy.**Test Parameters**: 1. GBA (Gaucher), 2. SMPD1 (Niemann-Pick A/B), 3. GLA (Fabry).**Pretest Condition**: No fasting required; patients should have organomegaly or pain.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on hepatosplenomegaly, pain crises.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected LSD including organ damage, benefits of screening, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Pathogenic mutation confirms treatable disorder, necessitating specialist input.**Specialist Consultation**: Pediatric metabolic specialists or geneticists should be consulted for management.**Additional Supporting Tests**: Enzyme assays, chitotriosidase for confirmation.**Test Limitations**: Focused panel; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, IEM Studies India 2023. |
